Assessment of the modulation degrees of intensity-modulated radiation therapy plans

Radiation Oncology

Table 2 Average values of global gamma passing rates of intensity modulated radiation therapy plans

	3%/3 mm			2%/2 mm			2%/1 mm			1%/2 mm
	MC	AC	p	MC	AC	p	MC	AC	p	MC	AC	p
TrueBeam
Lung SABR (n = 2)	98.5 ± 2.3	99.4 ± 0.6	< 0.001	93.8 ± 4.0	97.7 ± 1.7	< 0.001	85.3 ± 7.1	91.1 ± 3.6	< 0.001	75.2 ± 11.7	95.9 ± 2.7	< 0.001
Spine SABR (n = 20)	98.4 ± 2.7	99.3 ± 0.9	< 0.001	95.8 ± 4.1	97.9 ± 1.5	< 0.001	91.0 ± 7.1	87.6 ± 4.3	0.047	91.1 ± 4.3	95.6 ± 2.6	< 0.001
Liver SABR (n = 20)	99.2 ± 0.9	99.4 ± 1.2	< 0.001	96.7 ± 2.4	97.9 ± 3.1	< 0.001	92.7 ± 4.0	88.8 ± 7.3	0.013	91.1 ± 5.3	95.8 ± 4.7	< 0.001
Brain (n = 20)	98.8 ± 1.6	99.3 ± 2.4	0.002	96.4 ± 3.3	98.5 ± 4.2	0.002	91.6 ± 4.7	92.1 ± 7.3	0.761	89.8 ± 7.1	97.2 ± 4.9	< 0.001
Head and neck (n = 20)	96.2 ± 3.4	97.5 ± 3.6	0.072	84.8 ± 8.3	89.1 ± 10.3	0.107	74.5 ± 10.8	80.5 ± 13.9	0.996	66.3 ± 9.9	71.6 ± 13.0	0.001
Trilogy
Head and neck (n = 40)	99.4 ± 0.6	99.8 ± 0.7	0.088	96.3 ± 2.4	98.5 ± 2.1	< 0.001	90.1 ± 3.9	94.4 ± 3.7	0.003	87.8 ± 5.3	94.8 ± 3.9	< 0.001
Prostate primary (n = 21)	98.2 ± 0.8	99.5 ± 0.4	0.162	93.9 ± 1.4	97.1 ± 1.0	0.042	84.8 ± 3.0	86.1 ± 2.7	0.077	85.4 ± 1.7	93.4 ± 1.8	< 0.001
Prostate boost (n = 21)	97.3 ± 1.5	99.4 ± 0.5	0.624	89.4 ± 2.6	96.2 ± 1.9	0.187	78.9 ± 5.0	83.6 ± 4.9	0.043	73.1 ± 4.9	92.5 ± 2.9	0.005
Liver (n = 11)	99.2 ± 0.8	99.8 ± 0.2	0.418	97.3 ± 2.6	98.2 ± 1.4	0.083	93.9 ± 3.9	92.3 ± 4.2	0.814	90.4 ± 4.1	94.5 ± 2.9	< 0.001
Spine (n = 9)	99.2 ± 0.9	99.7 ± 0.4	0.246	96.4 ± 3.4	97.3 ± 1.6	0.152	91.5 ± 6.6	89.3 ± 6.8	0.135	91.0 ± 5.5	92.5 ± 2.5	0.153

Note: MC MapCHECK2™ detector array, AC ArcCHECK™ detector array, SABR Stereotactic ablative radiotherapy, Prostate primary Prostate primary plan, Prostate boost Prostate boost plan

ISSN: 1748-717X